mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations. - Wikidata - wikimedia - TriplyDB

mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.

mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.

http://www.wikidata.org/entity/Q34049613

about

Toward the use of precision medicine for the treatment of head and neck squamous cell carcinoma Identification of a Novel Proto-oncogenic Network in Head and Neck Squamous Cell Carcinoma Macrolide Antibiotics Exhibit Cytotoxic Effect under Amino Acid-Depleted Culture Condition by Blocking Autophagy Flux in Head and Neck Squamous Cell Carcinoma Cell Lines Expression of the chemokine CXCL14 and cetuximab-dependent tumour suppression in head and neck squamous cell carcinoma.Interplay between ΔNp63 and miR-138-5p regulates growth, metastasis and stemness of oral squamous cell carcinoma PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models.The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers Blockade of telomerase reverse transcriptase enhances chemosensitivity in head and neck cancers through inhibition of AKT/ERK signaling pathways Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial.Dysregulation of splicing proteins in head and neck squamous cell carcinoma.Role of Reactive Oxygen Species in the Abrogation of Oxaliplatin Activity by Cetuximab in Colorectal Cancer.Inactivating mutations in GNA13 and RHOA in Burkitt's lymphoma and diffuse large B-cell lymphoma: a tumor suppressor function for the Gα13/RhoA axis in B cells.The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma Impact of PI3K/AKT/mTOR pathway activation on the prognosis of patients with head and neck squamous cell carcinomas.Molecular profiling of head and neck squamous cell carcinoma.Identification of new candidate therapeutic target genes in head and neck squamous cell carcinomas.Dihydromyricetin promotes autophagy and apoptosis through ROS-STAT3 signaling in head and neck squamous cell carcinoma.Proteomic identification of cyclophilin A as a potential biomarker and therapeutic target in oral submucous fibrosis.Exceptional response to cetuximab monotherapy in a patient with metastatic oropharyngeal squamous cell carcinoma: a molecular insight.Personalizing Medicine in Head and Neck Squamous Cell Carcinoma: The Rationale for Combination Therapies Combination of phosphotidylinositol-3-kinase targeting with cetuximab and irradiation: A preclinical study on an orthotopic xenograft model of head and neck cancer.Investigational drugs for head and neck cancer.Combination of mTOR and EGFR targeting in an orthotopic xenograft model of head and neck cancer.Treatment of head and neck cancer in the elderly.mTOR co-targeting strategies for head and neck cancer therapy Leveraging Genomics for Head and Neck Cancer Treatment.BET inhibition overcomes receptor tyrosine kinase-mediated cetuximab resistance in HNSCC.Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma.Nuclear Klf4 accumulation is associated with cetuximab drug-resistance and predicts poor prognosis of nasopharyngeal carcinoma.

P2860

Q28074691-6C9DE767-490D-46A2-8799-8AC139222CE4 Q28834533-C70BC4D8-C998-4249-AEB4-111C87347867 Q30367534-96EF54CE-0E6B-42F7-8E11-C1FE41750BB6 Q33586751-8C1EFE05-4A60-4E60-AACB-27FC397236E5 Q33591763-DD590AD6-3C56-4F2B-9E90-A3B7B093A8DD Q33717395-54408E90-11AC-47EE-9B6D-6B1A04CE70E6 Q34619156-AD741CEA-3B35-4033-8BAA-D52DB112851A Q35925179-4F132B69-742C-441C-88A4-EBCC3DCAC2ED Q36546515-D4D6D2ED-222D-488C-8DD3-C6F5A4DD3F44 Q36631786-693FD825-621C-4FFD-A9D2-CCD42DC1AFD7 Q36844399-0FF518FB-4233-4540-AF08-8CDECFF7579F Q36895532-B07E899F-4189-4D44-B915-1A4DAE53C27E Q36948524-09314038-FE18-4C95-AA4D-C727ED6A9F90 Q37046726-429F5966-AB04-440B-87FA-67EF5D9DD6DE Q37301942-8C130DFD-1D95-44A0-8FB7-E8BDC24969EA Q37337359-7B335DE5-077B-4FD2-987A-652C81AF3110 Q37565157-60FB1A58-B659-4256-ABC5-D52B1233596A Q37644922-D3F24988-8F90-4497-A7A1-558A70983C12 Q37645025-C4179CA7-500E-449C-8FCC-5C7863A040CC Q38503146-B6D6CECF-0843-4D8A-89BF-830FEC741258 Q38586956-4FA00BB0-8F5C-47DB-88F5-047F5361C8D1 Q38752793-E21E1087-661D-455A-828F-82F30B22F140 Q38800788-A82750D7-5C95-4A1D-A261-459FD3714B61 Q38817479-B54A219C-FE03-4F62-90DB-0D0DD8807140 Q38958367-A932EC28-382F-4CD0-A96E-6923B386BD13 Q42363764-B2C4FA8B-1BB9-416B-ACBE-04B3E8E3EE4D Q50116331-379F9824-EB2C-4015-9E84-D740743C757E Q54978430-E383D5FF-60F8-4B93-AFB5-F4D29BC7655B Q54979771-DAED14B1-38CB-4B08-A1FD-8918F0BA130E Q55518643-D68C0F00-802B-4161-8E36-E7ECE3D2F856

P2860

mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.

http://www.wikidata.org/entity/Q34049613

description

2014 nî lūn-bûn

@nan

2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

mTOR co-targeting in cetuximab ...... ring PIK3CA and RAS mutations.

@ast

mTOR co-targeting in cetuximab ...... ring PIK3CA and RAS mutations.

@en

mTOR co-targeting in cetuximab ...... ring PIK3CA and RAS mutations.

@nl

type

label

mTOR co-targeting in cetuximab ...... ring PIK3CA and RAS mutations.

@ast

mTOR co-targeting in cetuximab ...... ring PIK3CA and RAS mutations.

@en

mTOR co-targeting in cetuximab ...... ring PIK3CA and RAS mutations.

@nl

prefLabel

mTOR co-targeting in cetuximab ...... ring PIK3CA and RAS mutations.

@ast

mTOR co-targeting in cetuximab ...... ring PIK3CA and RAS mutations.

@en

mTOR co-targeting in cetuximab ...... ring PIK3CA and RAS mutations.

@nl

P1433

Q34049613-8C6122CB-4E64-46DF-A0B4-066B4FAC0611

P1476

Q34049613-64251AC4-416A-474E-BA59-99C56671C560

P2093

Q34049613-0949325B-4257-46C3-AB90-9FD6B8D54A06

Q34049613-13B9C458-CAAF-415E-901A-CC729C08C624

Q34049613-281FE20D-8A8B-439F-B9EA-997216256616

Q34049613-4D08C756-448C-4290-8A61-519337E2D34F

Q34049613-5FA5AA8F-22AB-469A-8ED1-FBD3DD33E36B

Q34049613-818953C5-8560-4074-A780-539F3B9805FA

Q34049613-DA2A621E-055F-47A9-9F90-FE4D52D27E95

P2860

Q34049613-02517831-1B29-4EEC-BC89-228E3E87A42C

Q34049613-06F2D55F-5E7C-4178-9434-0C4D7DB6167D

Q34049613-0912145C-DB32-4CF1-99B4-1B4047F3AD30

Q34049613-0B975175-1B23-4B00-A88C-D6945201E8F5

Q34049613-0E692853-A84D-4E44-95A6-B77AF206444A

Q34049613-0E87A5BA-098D-4674-8299-C55C4E091920

Q34049613-1B349916-C4FA-43B1-9268-2425A6444CC4

Q34049613-229E42E9-7AC3-4E70-8DD6-207E57796855

Q34049613-266A6148-EE7D-42BE-817D-6A8007D7C20B

Q34049613-2AEC9BD2-F5D7-48F0-BFB6-1DE530BA89A0

P31

Q34049613-47A497E0-6720-4F57-AFE0-24EE977991BF

P356

Q34049613-99F9FEFD-9AA7-40E7-8610-2CD769E4ABAA

P407

Q34049613-BF427B12-18B9-403B-B492-34649214DB56

P433

Q34049613-E54A6382-0D28-463C-B26F-DD672B331E6D

P478

Q34049613-E7DF20A3-AEAA-4117-824F-EBB1C22861D6

P50

Q34049613-F014F484-B337-461A-8756-54A4764681DB

Q34049613-FA4E0B80-8EB7-49E6-865A-7468EBC5BA27

P577

Q34049613-A5D08A85-C83D-48A3-8990-1E570776BB79

P5875

Q34049613-0F1DCE5F-4E29-4F4D-AF70-0C24E105490F

P698

Q34049613-07F154E4-3F9E-4C26-95F0-CE0E9E56EC6B

P921

Q34049613-6027E2B5-AC47-49C2-AAB8-F1CC6F2D9F3B

P932

Q34049613-75085B82-B034-4E6D-A5A3-3D9822C23493

P356

P1433

Journal of the National Cancer Institute

P1476

mTOR co-targeting in cetuximab ...... ring PIK3CA and RAS mutations.

@en

P2093

Alfredo A Molinolo

http://www.w3.org/2001/XMLSchema#string

Daniel Martin

http://www.w3.org/2001/XMLSchema#string

Lynn Vitale-Cross

http://www.w3.org/2001/XMLSchema#string

Maria Sol Degese

http://www.w3.org/2001/XMLSchema#string

Qianming Chen

http://www.w3.org/2001/XMLSchema#string

Vyomesh Patel

http://www.w3.org/2001/XMLSchema#string

Zhiyong Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab

mTOR signaling in growth control and disease

The Catalogue of Somatic Mutations in Cancer (COSMIC)

Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival.

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.

Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers

Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition

Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells

Upstream and downstream of mTOR

P31

scholarly article

P356

10.1093/JNCI/DJU215

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P50

Ramiro Iglesias-Bartolome

J. Silvio Gutkind

P577

2014-08-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

264631299

http://www.w3.org/2001/XMLSchema#string

P698

25099740

http://www.w3.org/2001/XMLSchema#string

P921

P932

4133928

http://www.w3.org/2001/XMLSchema#string